Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 |
| | 10-K | 10-K | 10-K | 10-K | 10-K | S-1/A |
| Revenues: |
| Therapeutics | | | 21.9 | 20.6 | 9.5 | |
| Food | | | 2.4 | 1.6 | 1.4 | |
| Total revenues [+] | 25.1 | 115.5 | 24.3 | 22.2 | 10.9 | 6.5 |
| Royalties | | | | | | 20.3 |
| Revenue growth [+] | -78.3% | 375.7% | 9.2% | 104.3% | 67.8% | |
| Therapeutics | | | 6.0% | 116.7% | | |
| Food | | | 50.8% | 18.1% | | |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 28.3 |
| Gross profit | 25.1 | 115.5 | 24.3 | 22.2 | 10.9 | -21.9 |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | -337.1% |
| Selling, general and administrative [+] | 125.5 | 154.9 | 36.1 | 27.0 | 13.7 | 0.1 |
| General and administrative | | | 36.1 | 27.0 | 13.7 | |
| Research and development | | | 98.1 | 82.4 | 45.1 | |
| Other operating expenses | | -6.0 | | | | -0.1 |
| EBITDA [+] | -92.6 | -24.4 | -101.1 | -81.9 | -45.6 | -20.4 |
| EBITDA growth | 279.2% | -75.8% | 23.4% | 79.7% | 123.1% | |
| EBITDA margin | -368.8% | -21.1% | -416.1% | -368.2% | -418.6% | -314.9% |
| Depreciation | 7.7 | 9.0 | 8.8 | 5.3 | 2.3 | 1.4 |
| EBITA | -100.3 | -33.4 | -109.8 | -87.2 | -47.8 | -21.9 |
| EBITA margin | -399.5% | -28.9% | -452.2% | -392.1% | -439.3% | -337.1% |
| Amortization of intangibles | 0.1 | | | | 0.1 | |
| EBIT [+] | -100.4 | -33.4 | -109.8 | -87.2 | -47.9 | -21.9 |
| EBIT growth | 200.6% | -69.6% | 25.9% | 82.0% | 119.2% | |
| EBIT margin | -399.9% | -28.9% | -452.2% | -392.1% | -440.2% | -337.1% |
| Non-recurring items [+] | | 6.0 | | | | 0.1 |
| Asset impairment | | | | | | 0.1 |
| Unusual expense | | 6.0 | | | | |
| Interest income, net [+] | 3.5 | 0.2 | 0.8 | 4.1 | 1.9 | |
| Interest expense | 1.1 | 0.1 | | 0.2 | | |
| Interest income | 3.5 | 0.2 | 0.8 | 4.3 | 1.9 | |
| Other income (expense), net [+] | -13.6 | 8.7 | 0.0 | -9.8 | | 22.0 |
| Other | | | 0.8 | -5.7 | 1.9 | |
| Pre-tax income | -111.6 | -30.6 | -109.0 | -92.9 | -46.0 | 0.0 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | | 0.0% | 0.0% | |
| Net income | -111.6 | -30.6 | -109.0 | -92.9 | -46.0 | 0.0 |
| Net margin | -444.8% | -26.5% | -448.9% | -417.6% | -423.0% | 0.0% |
| |
| Basic EPS [+] | ($1.27) | ($0.52) | ($2.09) | ($2.21) | ($2.92) | $0.00 |
| Growth | 143.6% | -75.1% | -5.3% | -24.2% | | |
| Diluted EPS [+] | ($1.27) | ($0.52) | ($2.09) | ($2.21) | ($2.92) | $0.00 |
| Growth | 143.6% | -75.1% | -5.3% | -24.2% | | |
| |
| Shares outstanding (basic) [+] | 87.9 | 58.7 | 52.0 | 42.0 | 15.8 | 15,906.8 |
| Growth | 49.8% | 12.8% | 23.9% | 166.2% | -99.9% | |
| Shares outstanding (diluted) [+] | 87.9 | 58.7 | 52.0 | 42.0 | 15.8 | 15,906.8 |
| Growth | 49.8% | 12.8% | 23.9% | 166.2% | -99.9% | |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|